| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Decitabine |
| Brand | Dacogen® |
| Indication | For AML in patients who are >65yrs who are not candidates for standard induction therapy |
| Assessment Process | |
| Rapid review commissioned | 08/11/2012 |
| Rapid review completed | 13/12/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
05/12/2013 Following additional commercial discussions the HSE has approved reimbursement of Decitabine (Dacogen®) in the hospital setting.